A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs ASG 15ME (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agensys; Astellas Pharma
- 15 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 15 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 14 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.